Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with Stage II-III HER-2 (-) Breast Cancer

被引：0
|
作者：
Montero, A. J.
Diaz, C. M.
Slingerland, J.
Pegram, M.
Hurley, J.
Welsh, C. F.
Avisar, E.
Seo, P.
Vogel, C. L.
Garrett-Mayer, E.
Hermann, V.
Baker, M. K.
Silva, O.
Koniaris, L.
Rodgers, S.
Schuhwerk, K.
Pazoles, C. J.
Moffat, F.
Cole, D. J.
Gluck, S.
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA
[2] Med Univ S Carolina, Charleston, SC USA
[3] Novelos Therapeut, Newton, MA USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P1-11-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-05
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Results of Neoteam: A randomized multicenter phase II study of liposomal doxorubicin hydrochloride plus trastuzumab vs conventional doxorubicin both in combination with cyclophosphamide and followed by docetaxel plus trastuzumab as neoadjuvant treatment of HER2-positive primary breast cancer
    Pernas Simon, S.
    Rezai, M.
    Hauschild, M.
    Machiels, J. P.
    Paepke, S.
    Llombart Cussac, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)
    Kenjiro Aogi
    Toshiaki Saeki
    Seigo Nakamura
    Masahiro Kashiwaba
    Nobuaki Sato
    Norikazu Masuda
    Yoshiaki Rai
    Shinji Ohno
    Katsumasa Kuroi
    Reiki Nishimura
    Keiko Miyakoda
    Futoshi Akiyama
    Masafumi Kurosumi
    Tadashi Ikeda
    International Journal of Clinical Oncology, 2013, 18 : 598 - 606
  • [33] A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)
    Aogi, Kenjiro
    Saeki, Toshiaki
    Nakamura, Seigo
    Kashiwaba, Masahiro
    Sato, Nobuaki
    Masuda, Norikazu
    Rai, Yoshiaki
    Ohno, Shinji
    Kuroi, Katsumasa
    Nishimura, Reiki
    Miyakoda, Keiko
    Akiyama, Futoshi
    Kurosumi, Masafumi
    Ikeda, Tadashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (04) : 598 - 606
  • [34] A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer
    Hurvitz, S. A.
    Bosserman, L. D.
    Leland-Jones, B.
    Thirwell, M.
    Allison, M. K.
    Barstis, J.
    Molthrop, D.
    Quan, E.
    Upadhyaya, G.
    Slamon, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+early breast cancer
    Slamon, D. J.
    Eiermann, W.
    Robert, N. J.
    Giermek, J.
    Martin, M.
    Jasiowka, M.
    Mackey, J. R.
    Chan, A.
    Liu, M-C
    Pinter, T.
    Valero, V.
    Falkson, C.
    Fornander, T.
    Shiftan, T. A.
    Bensfia, S.
    Hitler, S.
    Xu, N.
    Bee-Munteanu, V.
    Drevot, P.
    Press, M. F.
    Crown, J.
    CANCER RESEARCH, 2016, 76
  • [36] Preferential pathologic complete response (pCR) in HER-2 positive and triple-negative breast cancer to sequential FEC 100-docetaxel (T) neoadjuvant chemotherapy (NCT) in stage II-III operable breast cancer
    Dubray, P.
    Durando, X.
    Abrial, C.
    Mouret-Reynier, M.
    Nayl, B.
    Thivat, E.
    Gimbergues, P.
    Achard, J.
    Chollet, P.
    Penault-Llorca, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Safety and efficacy of tow-dose pegfilgrastim (pegfil) in maintaining chemotherapy (CT) dose density in patients (pts) receiving docetaxel/doxorubicin/cyclophosphamide (TAC) or doxorubicin/cyclophosphamide (AC) as neoadjuvant chemotherapy (NCT) for stage II-III breast cancer (BC)
    Kim, E.
    Jin, R.
    Choi, K.
    Frankel, P. H.
    Somlo, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Response Rates to Neoadjuvant Cyclophosphamide and Doxorubicin (AC) in Breast Cancer Patients Exhibiting Her-2/Neu (Her-2) Negative, Topoisomerase II (TOPO 2A) Normal, Chromosome 17 (C17) Normal Phenotype
    Kaplan, H.
    Malmgren, J.
    Atwood, M.
    Wiseman, C.
    Goldstein, L.
    CANCER RESEARCH, 2009, 69 (24) : 602S - 603S
  • [39] Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study
    Burstein, HJ
    Harris, LN
    Gelman, R
    Lester, SC
    Nunes, RA
    Kaelin, CM
    Parker, LM
    Ellisen, LW
    Kuter, I
    Gadd, MA
    Christian, RL
    Kennedy, PR
    Borges, VF
    Bunnell, CA
    Younger, J
    Smith, BL
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 46 - 53
  • [40] Efficacy and safety of neoadjuvant treatment with liposomal doxorubicin, cyclophosphamide, paclitaxel and bevazicumab combination in locally/regionally advanced HER-2 negative, grade III premenopausal status breast cancer
    Tampaki, A. C.
    Tampakis, A.
    Alifieris, K.
    Kontos, M.
    Trafalis, D.
    BREAST, 2017, 32 : S82 - S82
12345